Physician profile
Andreas U Wali
NPI 1649273764
$5,754.11
in general payments reported to CMS, 2019-2025
28 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,294 · 2020: $114 · 2021: $379 · 2022: $1,570 · 2023: $335 · 2024: $673 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,662.47 | 2019 | |
| Edwards Lifesciences Corporation | $1,529.56 | 2019-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $690.63 | 2022-2025 | Silverhawk, Ffrangio, Corevalve Evolut R |
| Boston Scientific Corporation | $654.99 | 2021-2024 | Watchman, Watchman Access System, Avvigo Guidance System |
| E.R. Squibb & Sons, L.L.C. | $203.59 | 2019-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $165.17 | 2019-2022 | |
| Medtronic Vascular, INC. | $146.14 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $123.38 | 2021 | |
| Pfizer INC. | $115.17 | 2019 | |
| Cardiva Medical, INC. | $39.32 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Regeneron Healthcare Solutions, INC. | $38.89 | 2019 | |
| Abiomed | $38.05 | 2024 | Impella |
| Amgen INC. | $29.88 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.62 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $24.32 | 2024 | Artis Icono Biplane |
| Chiesi USA, INC. | $23.23 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $21.09 | 2024 | Arcalyst |
| Novo Nordisk INC | $19.08 | 2025 | |
| W. L. Gore & Associates, INC. | $16.31 | 2024 | Gore Cardioform Septal Occluder |
| Daiichi Sankyo INC. | $16.26 | 2023 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.72 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $14.92 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.33 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Wali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.